VENTYX BIOSCIENCES INC. news, videos and press releases
For more news please use our advanced search feature.
VENTYX BIOSCIENCES INC. - More news...
VENTYX BIOSCIENCES INC. - More news...
- Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
- Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress
- Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024
- Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi
- Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s Disease
- Ventyx Biosciences Announces Departure of Chief Financial Officer
- Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
- Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress
- Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Participants with Moderately to Severely Active Crohn’s Disease
- Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers
- Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
- Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer
- Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress
- Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024
- Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event
- Ventyx Biosciences Announces $100 Million Private Placement of Common Stock
- Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
- Ventyx Biosciences to Host Virtual Investor Event on March 11, 2024
- Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress
- Ventyx Biosciences to Present Results of the Phase 2 Trial of VTX002 in Ulcerative Colitis at the 19th Congress of the European Crohn's and Colitis Organisation (ECCO)
- Ventyx Biosciences to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Ventyx Biosciences to Participate in the 35th Annual Piper Sandler Healthcare Conference
- Ventyx Biosciences to Participate in the Jefferies London Healthcare Conference
- Ventyx Biosciences Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Progress
- Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Patients with Moderate to Severe Plaque Psoriasis and Provides Corporate Update
- Ventyx Biosciences Announces Positive Results from the Phase 2 Trial of VTX002 in Patients with Moderate-to-Severely Active Ulcerative Colitis
- Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
- Ventyx Biosciences Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate Progress
- Ventyx Biosciences to Report Second Quarter 2023 Financial Results on August 10, 2023
- Ventyx Biosciences to Participate in the Canaccord Genuity 43rd Annual Growth Conference
